A review of mitotane in the management of adrenocortical cancer Review
| Authors: | Del Rivero, J.; Else, T.; Hallanger-Johnson, J.; Kiseljak-Vassiliades, K.; Raj, N.; Reidy-Lagunes, D.; Srinivas, S.; Gilbert, J.; Vaidya, A.; Aboujaoude, E.; Bancos, I.; Tito Fojo, A. |
| Review Title: | A review of mitotane in the management of adrenocortical cancer |
| Abstract: | Importance: Mitotane (Lysodren, o,p'-DDD [1-(o-chlorophenyl)-1-(p-chlorophenyl)-2,2-dichloroethane)] is currently the only United States Food and Drug Administration and European Medicines Agency-approved product for the treatment of adrenocortical carcinoma. Observations: Mitotane is challenging to administer; however, its toxicities (specifically adrenal insufficiency) are well known, and the management of adverse consequences has established approaches. While often viewed through the prism of a cytotoxic agent, it can also interfere with hormone production making it a valuable asset in managing functional ACC. A recently completed prospective trial has shed some light on its use in the adjuvant setting, but further clarity is needed. Many think mitotane has a role in the advanced or metastatic setting, although prospective data are lacking and retrospective analyses are often difficult to interpret. Conclusions and relevance: When used carefully and thoughtfully, especially in patients with hormonal excess, mitotane is an important component of the treatment armamentarium for ACC. © 2024 Published by Oxford University Press. |
| Keywords: | review; side effect; food and drug administration; adrenal cortex carcinoma; drug combination; surgery; antineoplastic agents, hormonal; drug therapy; adverse drug reaction; antineoplastic hormone agonists and antagonists; mitotane; adrenocortical carcinoma; adrenal cortex tumor; adrenal cortex neoplasms; hormone synthesis; drug interaction; adrenal insufficiency; humans; human; rare tumors; adrenal cortex cancer; dichloroethane |
| Journal Title: | The Oncologist |
| Volume: | 29 |
| Issue: | 9 |
| ISSN: | 1083-7159 |
| Publisher: | Oxford University Press |
| Date Published: | 2024-09-01 |
| Start Page: | 747 |
| End Page: | 760 |
| Language: | English |
| DOI: | 10.1093/oncolo/oyae084 |
| PUBMED: | 39037424 |
| PROVIDER: | scopus |
| PMCID: | PMC11379655 |
| DOI/URL: | |
| Notes: | Review -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work